Noida:Jubilant Pharmovahas announced the appointment of Arun Kumar Sharma as a Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from October 1, 2025. He shall hold the CFO office for an interim period till the appointment of new CFO. "we wish to inform that the Board of Directors of the Company, at its meeting held on September 23, 2025, on the recommendation of Nomination, Remuneration and Compensation Committee and the Audit Committee, had considered and approved the appointment of Mr. Arun Kumar Sharma as a Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from October 1, 2025," the company stated in a BSE filing. "The appointment is made for an interim period to ensure a smooth transition to the new Chief Financial Officer, for which the identification and appointment process is in progress," it added. Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!